Proactive Investors - Run By Investors For Investors

Nanobiotix reports 'excellent' results from early stage liver cancer trial

The nanopaticles were administered by intra-tumoural (IT) injection and activated by high precision radiation therapy.
picture of cancer cell
Liver cancer is one of the hardest forms of the disease to treat

Cancer treatment group Nanobiotix (EPA:NANO) has reported ‘excellent’ results from an early stage trial of its nanoparticle technology in liver cancer sufferers.

The aim with trial with NBTXR3,  one of seven Nanobiotix has ongoing in various types of cancer, is to amplify the energy dose within the tumour in the liver to improve the result from treatment.

The nanopaticles were administered by intra-tumoural (IT) injection and activated by high precision radiation therapy.

Patients received a NBTXR3 dose equivalent to 10% of the tumour volume. The trial showed a good safety profile with no adverse events and no leakage on the healthy surrounding tissue.

Next steps will to increase the dosage to test for safety and tolerance.

Liver cancer is one of the hardest forms of the disease to treat as although it responds well to radiation therapy delivering the radioactive dose is complex.

Elsa Borghi, Nanobiotix’s chief medical officer, said: “At this stage, the safety and feasibility data of NBTXR3 in liver cancers are excellent.

“Observations are similar to the results of our more advanced trials: Soft Tissue Sarcoma and Head and Neck cancers.

 “This is significant because these trials cover very different patient and disease profiles.

“Based on the information gathered to date, we anticipate that by the end of this phase, we will have identified the appropriate conditions to use NBTXR3 in these patients populations.

 “Once again, all transferability data show the potential of broad applicability of NBTXR3 for use with radiotherapy in the treatment of solid tumors.” 

Nanobiotix’s nanopaticle treatment, NBTXR3 is injected into cancerous tumours where it absorbs the ionizing radiation delivered by radiotherapy and magnifies its effect locally. This shrinks the tumour making it easier to remove during surgery.

View full NANO profile View Profile

Nanobiotix SA Timeline

Related Articles

immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use